grant
Precision Therapy to Target Pancreatic Ductal Adenocarcinoma
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025Abdominal CavityAddressAntibodiesBehaviorBindingBloodBlood Reticuloendothelial SystemBlood VesselsCancer PatientCavitas abdominisCell LineCell surfaceCellLineClinical TrialsCollaborationsDataDepositDepositionDiseaseDisorderDrugsEXTMRExtramuralExtramural ActivitiesGoalsHeartHumanImmuneImmune systemImmunesImmunocompetentImpairmentKnock-inLungLung Respiratory SystemMacrophageMalignant CellMalignant Pancreatic NeoplasmMalignant neoplasm of pancreasManuscriptsMedicalMedicationMembraneMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorMiceMice MammalsModelingModern ManMolecular InteractionMurineMusMφNeoplasm MetastasisNormal CellPDA modelPDAC ModelPDAC cancer cellPDAC cellPancreas CancerPancreas Ductal AdenocarcinomaPancreatic CancerPancreatic Ductal AdenocarcinomaPatientsPenetrationPeritonealPeritoneumPharmaceutical PreparationsPhysiologyPrecision therapeuticsPublishingRoleSecondary NeoplasmSecondary TumorSoluble Mpf/Mesothelin-Related ProteinStrains Cell LinesTestingTherapeuticTumor AntigensTumor CellTumor-Associated AntigenWorkWound RepairWritingadvanced diseaseadvanced illnesscancer antigenscancer cellcancer metastasiscultured cell linedensitydesigndesigningdrug/agentimmune competentimprovedknockinmembrane structuremesothelinneoplastic cellpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpancreatic malignancyprecision therapiesprecision treatmentresistance to therapyresistant to therapysocial roletargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic resistancetherapy resistanttreatment resistancetumortumor cell metastasistumor-specific antigentumorigenicvascularwound healingwound recoverywound resolution
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
GOAL A (completed)- MSLN is the target of many therapeutics being tested in clinical trials but little is understood about the effect of MSLN on PDAC aggressiveness and therapeutic resistance. We have previously found that loss of MSLN impairs the ability of PDAC to colonize the peritoneum and cause metastasis there. MSLN loss from cancer cells…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click